Nanobiotix
NBTX
Performance
About Nanobiotix
Nanobiotix is a biotechnology company focused on discovering, developing, manufacturing, and commercializing physics-based nanomedicines for cancer therapy. The company specializes in leveraging nanomaterials to enhance radiotherapy and oncology treatments, aiming to improve patient outcomes across international markets. With research and operations spanning global locations, Nanobiotix positions itself at the intersection of nanomedicine and cancer biology, pursuing novel approaches to treatment. The organization emphasizes scientific innovation, clinical development, and partnerships across the biopharma ecosystem.
Recent News
Sapu Nano Doses First Patient in Phase 1b Trial of IV Deciparticle Everolimus
Nanobiotix Secures FDA Acceptance of Protocol Amendment to Accelerate Phase 3 NANORAY-312 Trial
Nanobiotix's Nanoprimer Boosts LNP‑DNA Immunotherapy Bioavailability, Cuts Toxicity
Europe’s Best-Performing Stocks of 2026 — Including One up by 947%
Voting Rights and Shares Capital of the Company
Nanobiotix's Phase‑2 Lung Cancer Trial Shows 85.7% Response Rate
Recent Deals
No recent deals for this company.